{"protocolSection":{"identificationModule":{"nctId":"NCT06477276","orgStudyIdInfo":{"id":"2024LLSD160-001"},"organization":{"fullName":"Ruijin Hospital","class":"OTHER"},"briefTitle":"Amygdala TIS for Depression","officialTitle":"A Multicenter, Randomized, Controlled, Double-Blind Trial on the Efficacy and Safety of Amygdala Temporal Interference Stimulation for the Treatment of Depression."},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-24","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-05-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-05-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-20","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"ZHANG CHENCHEHG","investigatorTitle":"Clinical Neuroscience Center Deputy Director","investigatorAffiliation":"Ruijin Hospital"},"leadSponsor":{"name":"Ruijin Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes. The intervention's safety and efficacy will be evaluated using an assessment incorporating depressive symptomatology, cognitive abilities, and daily functions."},"conditionsModule":{"conditions":["Major Depressive Disorder"],"keywords":["Deep Brain Stimulation","Non-invasive","TI","Amygdala","Temporal Interference"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":92,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Amygdala TI","type":"EXPERIMENTAL","interventionNames":["Device: Nervio-X"]},{"label":"Controlled TI","type":"SHAM_COMPARATOR","interventionNames":["Device: Nervio-X"]}],"interventions":[{"type":"DEVICE","name":"Nervio-X","description":"An 8-channel TIS device developed by NEURODOME Corporation.","armGroupLabels":["Amygdala TI","Controlled TI"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Hamilton Depression Rating Scale (17-item version)","timeFrame":"Baseline, 1 week, 4 weeks and 8 weeks"}],"secondaryOutcomes":[{"measure":"Hamilton Depression Rating Scale (6-item version)","timeFrame":"treatment completion day"},{"measure":"Snaith-Hamilton Pleasure Scale","description":"The SHAPS is a questionnaire that used to measure the severity of anhedonia, a common symptom in various mental health conditions.","timeFrame":"Baseline, 1 week, 4 weeks and 8 weeks"},{"measure":"Quick Inventory of Depressive Symptomatology - Self-Report (16-item version)","timeFrame":"Baseline, 1 week, 4 weeks and 8 weeks"},{"measure":"Hamilton Anxiety Rating Scale","timeFrame":"Baseline, 4 weeks and 8 weeks"},{"measure":"Pittsburgh Sleep Quality Index","timeFrame":"Baseline, 4 weeks and 8 weeks"},{"measure":"36-Item Short Form Health Survey","timeFrame":"Baseline and 8 weeks"},{"measure":"World Health Organization Quality of Life Assessment - Brief Version","timeFrame":"Baseline and 8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must be aged between 18 and 65, with no gender restrictions;\n* A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);\n* HAMD-17 score of 17 or higher;\n* Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;\n* Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol and provide their signature on the informed consent form.\n\nExclusion Criteria:\n\n* Eligible participants must not have a history of psychiatric disorders such as schizophrenia, as judged by the investigator, which may impact the evaluation of the study's efficacy;\n* Participants must not have a history of seizures or prior episodes of epilepsy;\n* The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;\n* Participants must not have a diagnosis of organic brain disease nor a history of significant cranial trauma or neurosurgical intervention;\n* Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy);\n* The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;\n* Pregnant or breastfeeding;\n* Participants who are concurrently engaged in other clinical interventional trials;\n* Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Chencheng Zhang","role":"CONTACT","phone":"021-64370045","email":"i@cczhang.org"}],"locations":[{"facility":"Ruijin Hospital","status":"RECRUITING","city":"Shanghai","state":"Shanghai","zip":"200025","country":"China","contacts":[{"name":"Chencheng Zhang","role":"CONTACT","email":"i@cczhang.org"}],"geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Pudong New Area Mental Health Center","status":"NOT_YET_RECRUITING","city":"Shanghai","country":"China","contacts":[{"name":"Jingjing Huang","role":"CONTACT"}],"geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai East Hospital","status":"NOT_YET_RECRUITING","city":"Shanghai","country":"China","contacts":[{"name":"Chuanyuan Kang","role":"CONTACT"}],"geoPoint":{"lat":31.22222,"lon":121.45806}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000003866","term":"Depressive Disorder"},{"id":"D000003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D000019964","term":"Mood Disorders"},{"id":"D000001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M7058","name":"Depression","relevance":"LOW"},{"id":"M7061","name":"Depressive Disorder","asFound":"Depressive Disorder","relevance":"HIGH"},{"id":"M7060","name":"Depressive Disorder, Major","asFound":"Major Depressive Disorder","relevance":"HIGH"},{"id":"M21835","name":"Mood Disorders","relevance":"LOW"},{"id":"M14473","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M4815","name":"Mental Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}